Compare SPGI & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPGI | MRK |
|---|---|---|
| Founded | 1860 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.5B | 268.7B |
| IPO Year | 1994 | 1994 |
| Metric | SPGI | MRK |
|---|---|---|
| Price | $436.14 | $115.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 17 |
| Target Price | ★ $562.67 | $125.59 |
| AVG Volume (30 Days) | 1.8M | ★ 6.7M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | 0.90% | ★ 2.88% |
| EPS Growth | ★ 18.70 | 8.01 |
| EPS | ★ 14.66 | 7.28 |
| Revenue | $6,063,000,000.00 | ★ $65,011,000,000.00 |
| Revenue This Year | $9.69 | $3.73 |
| Revenue Next Year | $7.38 | $5.42 |
| P/E Ratio | $29.42 | ★ $16.23 |
| Revenue Growth | ★ 7.10 | 1.31 |
| 52 Week Low | $381.61 | $75.40 |
| 52 Week High | $579.05 | $125.14 |
| Indicator | SPGI | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 40.30 |
| Support Level | $401.95 | $113.27 |
| Resistance Level | $446.83 | $124.57 |
| Average True Range (ATR) | 10.47 | 2.85 |
| MACD | 2.10 | -0.44 |
| Stochastic Oscillator | 85.21 | 8.40 |
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).